Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • IL Receptor
    (2)
  • Interleukin
    (2)
  • PI3K
    (2)
  • Antibacterial
    (1)
  • Antibiotic
    (1)
  • GST
    (1)
  • HSP
    (1)
  • STAT
    (1)
  • Others
    (5)
Filter
Search Result
Results for "

sta 2

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    8
    TargetMol | All_Pathways
  • Natural Products
    1
    TargetMol | Natural_Products
  • Recombinant Protein
    1
    TargetMol | Recombinant_Protein
STA 2
STA-2, STA2, ONO 11113
T3471089617-02-7
STA 2 is an analogue of TXA2, a thromboxane receptor in the colonic epithelium.
  • Inquiry Price
10-14 weeks
Size
QTY
GSTO-IN-2
T115041202710-57-3
GSTO-IN-2 is a glutathione S-transferase inhibitor with IC50 values of 1.4 μM for GSTP1-1, 16.3 μM for GSTM1, and 3.6 μM for GSTA2.
  • $599
In Stock
Size
QTY
Ochromycinone
STA-21, STA21, STA 21
T6995111540-00-2
Ochromycinone (STA 21) is a selective STAT3 inhibitor.
  • $98
In Stock
Size
QTY
TargetMol | Citations Cited
S 135
T71542104679-67-6
S 135 is a benzodiazepine receptor inverse agonist.
  • $1,520
6-8 weeks
Size
QTY
STA-2842
T715441046490-67-8
STA-2842 is an inhibitor of heat shock protein 90 (HSP90).
  • $1,520
6-8 weeks
Size
QTY
Apilimod
STA 5326
T2018541550-19-0
Apilimod (STA 5326) inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis.
  • $43
In Stock
Size
QTY
Apilimod mesylate
STA 5326 mesylate
T3533870087-36-8
Apilimod mesylate (STA 5326 mesylate) is a potent IL-12/IL-23 inhibitor.
  • $30
In Stock
Size
QTY
STA-9584
T68400906481-23-0
STA-9584 is a potent vascular disrupting agent, which exhibits potent antitumor activity by selectively targeting microvasculature at both the center and periphery of tumors. In vitro, 2-methoxy-5-(5-(3,4,5-trimethoxyphenyl)isoxazol-4-yl)aniline (STA-9122) (active metabolite of STA-9584 ) displayed increased potency relative to other tubulin-binding agents and was highly cytotoxic to tumor cells. STA-9584 induced significant tumor regressions in prostate and breast xenograft models in vivo and, in an aggressive syngeneic model, demonstrated superior tumor growth inhibition and a positive therapeutic index relative to combretastatin A-4 phosphate (CA4P).
  • $1,820
8-10 weeks
Size
QTY